Brian S Posner, a director at $DYN, bought 2,000 shares of the company on 03-11-2026 for an estimated $38,700. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings of this class of stock by approximately 17.4%. Following this trade, they now own 13,500 shares of this class of $DYN stock.
$DYN Insider Trading Activity
$DYN insiders have traded $DYN stock on the open market 13 times in the past 6 months. Of those trades, 2 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $DYN stock by insiders over the last 6 months:
- DIRK KERSTEN has made 0 purchases and 5 sales selling 818,460 shares for an estimated $15,679,875.
- JOHN COX (CEO & President) has made 0 purchases and 2 sales selling 5,394 shares for an estimated $95,863.
- BRIAN S POSNER has made 2 purchases buying 5,000 shares for an estimated $83,880 and 0 sales.
- DOUGLAS KERR (Chief Medical Officer) has made 0 purchases and 2 sales selling 1,784 shares for an estimated $31,703.
- JOHANNA FRIEDL-NADERER (Chief Commercial Officer) has made 0 purchases and 2 sales selling 292 shares for an estimated $5,188.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$DYN Hedge Fund Activity
We have seen 146 institutional investors add shares of $DYN stock to their portfolio, and 105 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 9,714,392 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $122,887,058
- ORBIS ALLAN GRAY LTD added 4,801,928 shares (+inf%) to their portfolio in Q4 2025, for an estimated $93,925,711
- PERCEPTIVE ADVISORS LLC added 2,938,500 shares (+543.7%) to their portfolio in Q4 2025, for an estimated $57,477,059
- VESTAL POINT CAPITAL, LP removed 2,655,000 shares (-95.7%) from their portfolio in Q4 2025, for an estimated $51,931,800
- MARSHALL WACE, LLP removed 2,336,398 shares (-77.5%) from their portfolio in Q4 2025, for an estimated $45,699,944
- CITADEL ADVISORS LLC removed 2,241,811 shares (-65.7%) from their portfolio in Q4 2025, for an estimated $43,849,823
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,898,950 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $37,143,462
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$DYN Analyst Ratings
Wall Street analysts have issued reports on $DYN in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 12/11/2025
- Oppenheimer issued a "Outperform" rating on 12/10/2025
- Chardan Capital issued a "Buy" rating on 12/09/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/06/2025
To track analyst ratings and price targets for $DYN, check out Quiver Quantitative's $DYN forecast page.
$DYN Price Targets
Multiple analysts have issued price targets for $DYN recently. We have seen 8 analysts offer price targets for $DYN in the last 6 months, with a median target of $38.5.
Here are some recent targets:
- Keay Nakae from Chardan Capital set a target price of $38.0 on 03/09/2026
- Ananda Ghosh from HC Wainwright & Co. set a target price of $50.0 on 03/03/2026
- Michael Ulz from Morgan Stanley set a target price of $47.0 on 03/03/2026
- Tessa Romero from JP Morgan set a target price of $16.0 on 01/20/2026
- Gavin Clark-Gartner from Evercore ISI Group set a target price of $36.0 on 12/15/2025
- Paul Matteis from Stifel set a target price of $39.0 on 12/11/2025
- Andreas Argyrides from Oppenheimer set a target price of $40.0 on 12/10/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
